Bio-Rad Laboratories Class A
About: Bio-Rad Laboratories, headquartered in Hercules, California, develops, manufactures, and sells products and solutions for the clinical diagnostics and life sciences markets. In clinical diagnostics (60% of sales), Bio-Rad sells test systems and specialized quality controls for clinical laboratories. In life sciences (40% of sales), it develops and manufactures instruments and reagents used in research, biopharmaceutical production, and food testing and has a leadership position in dPCR technology. The company is geographically diverse, with major markets in the Americas (about 40% of sales), Europe (about 30%), Asia (about 30%), and other. Bio-Rad owns approximately 33% of Sartorius, a lab and bioprocessing supplier that specializes in single-use technology used in biologics manufacturing.
Employees: 7,700
Fund manager confidence
Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)
25% more funds holding in top 10
Funds holding in top 10: 4 [Q1] → 5 (+1) [Q2]
2.44% more ownership
Funds ownership: 84.22% [Q1] → 86.67% (+2.44%) [Q2]
1% less capital invested
Capital invested by funds: $4.68B [Q1] → $4.63B (-$44.1M) [Q2]
12% less funds holding
Funds holding: 428 [Q1] → 377 (-51) [Q2]
32% less repeat investments, than reductions
Existing positions increased: 112 | Existing positions reduced: 165
45% less first-time investments, than exits
New positions opened: 54 | Existing positions closed: 99
67% less call options, than puts
Call options by funds: $2.94M | Put options by funds: $8.81M
Research analyst outlook
2 Wall Street Analysts provided 1 year price targets over the past 3 months
2 analyst ratings
|
RBC Capital
Conor McNamara
|
$409
|
Outperform
Maintained
|
1 Aug 2025 |
|
Wells Fargo
Brandon Couillard
|
$265
|
Equal-Weight
Maintained
|
1 Aug 2025 |
Financial journalist opinion
Based on 4 articles about BIO published over the past 30 days
